Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    85.7%

    Based on 6 completed trials

    Completion Rate
    86%(6/7)
    Active Trials
    0(0%)
    Results Posted
    50%(3 trials)
    Terminated
    1(10%)

    Phase Distribution

    Phase 1
    2
    20%
    Phase 2
    6
    60%
    Phase 3
    2
    20%

    Phase Distribution

    2

    Early Stage

    6

    Mid Stage

    2

    Late Stage

    Phase Distribution10 total trials
    Phase 1Safety & dosage
    2(20.0%)
    Phase 2Efficacy & side effects
    6(60.0%)
    Phase 3Large-scale testing
    2(20.0%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    85.7%

    6 of 7 finished

    Non-Completion Rate

    14.3%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    10

    all time

    Status Distribution
    Completed(6)
    Terminated(1)
    Other(3)

    Detailed Status

    Completed6
    unknown2
    Terminated1
    Suspended1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    10
    Active
    0
    Success Rate
    85.7%
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 12 (20.0%)
    Phase 26 (60.0%)
    Phase 32 (20.0%)

    Trials by Status

    completed660%
    terminated110%
    unknown220%
    suspended110%

    Recent Activity

    0 active trials
    Showing 5 of 10
    unknownphase_2

    Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children

    NCT01593488
    completedphase_2

    CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis

    NCT01325194
    completedphase_3

    Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer

    NCT01645839
    completedphase_2

    Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

    NCT00392834
    completedphase_2

    Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma

    NCT00073957
    View all 10 trials

    Clinical Trials (10)

    Showing 10 of 10 trials
    NCT01593488Phase 2

    Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children

    Unknown
    NCT01325194Phase 2

    CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis

    Completed
    NCT01645839Phase 3

    Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer

    Completed
    NCT00392834Phase 2

    Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

    Completed
    NCT00073957Phase 2

    Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma

    Completed
    NCT00992602Phase 2

    Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer

    Completed
    NCT01563614Phase 1

    A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain

    Terminated
    NCT00002704Phase 2

    Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia

    Completed
    NCT00991744Phase 3

    Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)

    Suspended
    NCT00003073Phase 1

    Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors

    Unknown

    All 10 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    10